A Medicine Can Work in the Lab and Still Fail to Reach the Right Cells
A drug can destroy diseased cells in a laboratory and still struggle to become an effective treatment. Nanomedicine research reveals why reaching the correct tissue and cells is one of medicine's hardest transportation problems, and how nanoparticles are being engineered to help.
ALL BLOGSSCIENCE
Imagine researchers discovering a molecule that can kill cancer cells in a laboratory dish. Under the microscope, the result looks promising. The cells respond. The mechanism makes sense. It would be easy to think the hardest part is over. But now that same molecule has to enter a human body. Suddenly, the journey becomes much more complicated. The treatment may have to survive in the bloodstream, avoid being removed too quickly, cross blood-vessel walls, move through tissue, reach enough of the intended cells, enter those cells when necessary, and sometimes escape compartments inside them before the drug can act. Researchers studying targeted nanomedicine describe these as multiple biological barriers, including systemic distribution, tissue penetration, and intracellular trafficking. This is one reason a medicine can be biologically powerful and still have a delivery problem. Nanomedicine tries to change that journey by packaging or carrying therapeutic substances at the nanoscale. But nanoparticles are not microscopic GPS systems. They face barriers too.
What Is Nanomedicine Actually Trying to Deliver?
Nanomedicine is a broad field, but one major application is using nanoscale structures as carriers for therapeutic cargo. That cargo can include small-molecule drugs, proteins, or nucleic acids. One well-established example is the liposome, a small lipid-based vesicle capable of carrying drugs. Liposomal formulations can protect some drugs from degradation or clearance and alter how they are released and distributed in the body. Several liposomal products have already received regulatory approval, so nanomedicine is not entirely futuristic laboratory science. The carrier matters because the active molecule is only part of a medicine's story. A drug also needs to exist in a form that allows an effective amount of it to reach the biological location where it is supposed to work.
Why Is Reaching the Right Cells So Difficult?
The human body was not designed to make drug delivery easy. Many of the barriers frustrating scientists are the same defenses that help keep us alive. Blood vessels regulate what moves from circulation into tissues. Cell membranes separate the inside of a cell from its surroundings. The immune system recognizes and removes foreign material. In targeted delivery, a nanoparticle may encounter dilution and nonspecific distribution while circulating, difficulty entering the desired tissue, limited movement through that tissue, and additional obstacles after entering a cell. Researchers therefore cannot design a carrier only around the drug. They have to think about the entire route. A nanoparticle that circulates beautifully but cannot penetrate the target tissue has not solved the problem. Neither has one that reaches a cell but cannot deliver its cargo where that cargo needs to act.
Who Could Benefit From Better Drug Delivery?
Cancer provides one of the clearest examples because scientists often want a treatment to affect malignant tissue while limiting unnecessary exposure elsewhere. But tumors are difficult delivery environments. Abnormal blood vessels, elevated interstitial pressure, and dense extracellular matrix can restrict how nanoparticles move through solid tumors. Researchers have also identified tumor vascular and stromal barriers that can interfere with nanoparticle escape from blood vessels and penetration deeper into tumor tissue. This is why "targeted" should not be interpreted as "the treatment goes only to the tumor." Even engineered nanocarriers can distribute outside their intended destination. Better targeting is a goal and, in some systems, an advantage. Perfect targeting is a much stronger claim than current evidence supports.
When Does the Carrier Change What a Drug Can Do?
Sometimes the carrier changes the pharmacological situation without changing the active drug itself. Liposomes, for example, can encapsulate therapeutic compounds and alter properties such as circulation, protection from degradation, release, and distribution. That distinction is important. Nanomedicine does not necessarily mean scientists have discovered a completely new molecule capable of treating disease. Sometimes scientists are trying to deliver a therapeutic substance differently. The first liposomal nanoscale drug reached clinical approval in 1995, and additional liposomal medicines have followed. So the central question becomes more interesting than "Does this molecule work?" Researchers may also need to ask: Can we package it in a way that changes where it goes, how long it remains available, or how safely it can be administered?
Where Do Nanoparticles Get Stuck?
Almost anywhere along the route. Consider a nanoparticle carrying an anticancer drug. After administration, it must remain sufficiently stable in biological fluids. It must circulate rather than being eliminated before accomplishing its job. It then has to reach the tumor vasculature, cross toward tumor tissue, and penetrate an environment that may contain dense extracellular matrix and abnormal pressure. If the target is inside a cancer cell, additional barriers appear. Reviews of targeted nanomedicine specifically identify intracellular trafficking as another delivery challenge. Even modern nanomedicine therefore faces a strange problem: the delivery vehicle created to overcome biological barriers encounters its own set of biological barriers. That is why nanoparticle design involves properties such as size, shape, surface characteristics, and composition rather than simply making a particle "small."
How Do Scientists Engineer Around These Barriers?
There is no single nanoparticle design that works for every drug and tissue. Researchers can alter particle size, shape, surface chemistry, and other physicochemical characteristics because these properties influence how particles interact with biological systems. Some nanoparticles are also functionalized with molecules intended to improve interactions with particular biological targets. Other approaches focus on improving circulation, tissue penetration, cellular entry, or controlled cargo release. But each improvement can introduce another design problem. A carrier optimized for one stage of delivery may perform less effectively at another. Reviews of tumor nanomedicine repeatedly describe this multistage journey as one of the reasons clinical translation remains difficult. Designing the particle is therefore not simply a matter of making it more sophisticated. Every added feature has to produce a useful biological advantage without making manufacturing, safety, stability, or reproducibility unacceptable.
Real-Life Example
Imagine a delivery driver carrying an extremely valuable package. The package itself is perfect. The problem is the address. First, the driver enters a city with thousands of roads. Some streets are blocked. Security checkpoints remove unfamiliar vehicles. The destination is behind a wall, and even after crossing the wall, the driver has to find one particular building. Nanomedicine is not literally navigating the body like a driver, but the comparison helps show why having the right cargo is not enough. A therapeutic molecule can possess exactly the biological activity scientists want while still facing barriers between administration and its site of action. Nanocarriers attempt to change parts of that journey. The important difference is that nanoparticles do not "know" where they are going. Their behavior comes from their physical and chemical properties and their interactions with biological systems.
Common Misconceptions About Targeted Nanomedicine
The biggest misconception is that nanoparticles can simply be programmed to travel directly to one diseased cell while ignoring everything else. Real biological systems are much messier. Reviews of targeted nanomedicine still identify nonspecific distribution, tissue penetration, intracellular trafficking, and other barriers as major unresolved problems. Another misconception is that nanomedicine is entirely experimental. Liposomal medicines already have a history of clinical approval and use. At the same time, it would be equally misleading to imply that the field has solved targeted delivery. A 2023 review noted that the number of nanodrugs reaching clinical treatment remains limited relative to the enormous research activity in the field, with challenges including complex formulations, tumor heterogeneity, manufacturing scale-up, cost, and regulatory uncertainty. Nanomedicine has real clinical successes and real limitations at the same time.
What You Can Learn From This
When you hear that scientists have discovered a molecule capable of destroying a particular type of cell, do not assume that discovery automatically becomes a medicine. Ask the next question: Can enough of it reach the right biological location safely? Drug development is not only molecular discovery. It is also a transportation problem occurring inside one of the most complicated environments imaginable. Nanomedicine gives researchers another set of tools for addressing that problem, especially because nanoparticle properties can be engineered around particular delivery challenges. But the body does not become passive just because the carrier is nanoscale. The same biological systems protecting tissues from unwanted substances also shape what happens to a therapeutic carrier.
Final Thoughts
Under a microscope, distance can look small. Inside a human body, the distance between a drug and its target can contain blood, vessel walls, extracellular material, cell membranes, immune interactions, and intracellular compartments. Each one can change whether a promising therapy actually reaches the place where it is needed. Nanomedicine grew partly from the idea that changing the delivery system could change what becomes therapeutically possible. That idea has already produced approved medicines, especially liposomal formulations. Yet current research is equally clear about the remaining barriers. Scientists are still working on circulation, selective distribution, tissue penetration, cellular delivery, manufacturing, and clinical translation. The molecule matters. The target matters. But between them is a journey, and sometimes that journey decides whether promising science ever becomes useful medicine.
References
Veiga N, et al. Targeted Nanomedicine: Lessons Learned and Future Directions. Journal of Controlled Release. 2023;355:446–457. PMID: 36773958. PubMed direct article page
Blanco E, Shen H, Ferrari M. Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery. Nature Biotechnology. 2015;33(9):941–951. PMID: 26348965. PMCID: PMC4978509.
PubMed direct article page
Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules. 2022;27(4):1372. PMID: 35209162. PMCID: PMC8879473. PubMed direct article page
Zhang Y, et al. Engineering Nanoparticles to Tackle Tumor Barriers. Journal of Controlled Release. 2020. PMID: 32579660. PubMed direct article page
Progress and Challenges in the Translation of Cancer Nanomedicines. Current Opinion in Biotechnology. 2024. PMID: 38096768. PubMed direct article page
Powered by TeenToMD.com © 2026
TeenToMD is an independent student-led educational platform created to promote science, wellness, neuroscience, mindset, and health literacy for general learning purposes.
TeenToMD content is educational and informational only. It does not provide medical advice, diagnosis, treatment, or emergency medical guidance. Please consult a licensed healthcare professional for personal medical concerns.